Your browser doesn't support javascript.
loading
High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition.
Cai, Jinyang; Jacob, Sheeba; Kurupi, Richard; Dalton, Krista M; Coon, Colin; Greninger, Patricia; Egan, Regina K; Stein, Giovanna T; Murchie, Ellen; McClanaghan, Joseph; Adachi, Yuta; Hirade, Kentaro; Dozmorov, Mikhail; Glod, John; Boikos, Sosipatros A; Ebi, Hiromichi; Hao, Huaixiang; Caponigro, Giordano; Benes, Cyril H; Faber, Anthony C.
Affiliation
  • Cai J; Philips Institute for Oral Health Research, School of Dentistry, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
  • Jacob S; Philips Institute for Oral Health Research, School of Dentistry, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
  • Kurupi R; Philips Institute for Oral Health Research, School of Dentistry, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
  • Dalton KM; Philips Institute for Oral Health Research, School of Dentistry, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
  • Coon C; Philips Institute for Oral Health Research, School of Dentistry, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
  • Greninger P; Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
  • Egan RK; Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
  • Stein GT; Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
  • Murchie E; Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
  • McClanaghan J; Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
  • Adachi Y; Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya, Aichi 464-8681, Japan.
  • Hirade K; Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya, Aichi 464-8681, Japan.
  • Dozmorov M; Department of Biostatistics, Virginia Commonwealth University, Richmond, VA 23298, USA.
  • Glod J; National Cancer Institute, Pediatric Branch, Oncology, Bethesda, MD, USA.
  • Boikos SA; Department of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.
  • Ebi H; Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya, Aichi 464-8681, Japan.
  • Hao H; Novartis Institute for Biological Research, 250 Massachusetts Avenue, Cambridge, MA 02139, USA.
  • Caponigro G; Novartis Institute for Biological Research, 250 Massachusetts Avenue, Cambridge, MA 02139, USA.
  • Benes CH; Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA. Electronic address: cyrilbenes@gmail.com.
  • Faber AC; Philips Institute for Oral Health Research, School of Dentistry, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA. Electronic address: acfaber@vcu.edu.
Cell Rep ; 40(4): 111095, 2022 07 26.
Article in En | MEDLINE | ID: mdl-35905710
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Neurofibromin 1 / Protein Tyrosine Phosphatase, Non-Receptor Type 11 / Neuroblastoma Type of study: Etiology_studies / Risk_factors_studies Limits: Animals Language: En Journal: Cell Rep Year: 2022 Type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Neurofibromin 1 / Protein Tyrosine Phosphatase, Non-Receptor Type 11 / Neuroblastoma Type of study: Etiology_studies / Risk_factors_studies Limits: Animals Language: En Journal: Cell Rep Year: 2022 Type: Article Affiliation country: United States